CRMD logo

CRMD
CorMedix Inc

23,476
Mkt Cap
$601.16M
Volume
5.29M
52W High
$17.43
52W Low
$5.60
PE Ratio
3.48
CRMD Fundamentals
Price
$7.30
Prev Close
$7.63
Open
$7.58
50D MA
$10.89
Beta
1.06
Avg. Volume
2.69M
EPS (Annual)
-$0.3046
P/B
1.50
Rev/Employee
$668,802.61
News
all
press releases
CorMedix (NASDAQ:CRMD) Trading Down 6.2% - Should You Sell?
CorMedix (NASDAQ:CRMD) Stock Price Down 6.2% - Should You Sell...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
Zacks·10h ago
News Placeholder
MDGL Secures Exclusive Global Right for MASH Treatment From PFE
Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.
Zacks·13h ago
News Placeholder
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
Zacks·14h ago
News Placeholder
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
Zacks·14h ago
News Placeholder
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
Zacks·15h ago
News Placeholder
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
Zacks·15h ago
News Placeholder
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.
Zacks·4d ago
News Placeholder
Are Investors Undervaluing CorMedix (CRMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·4d ago
News Placeholder
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
Zacks·4d ago
<
1
2
...
>

Latest CRMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.